查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1573228

化療噁心和嘔吐治療市場：按藥物類別、給藥途徑和最終用戶 - 2025-2030 年全球預測

Chemotherapy Induced Nausea & Vomiting Treatment Market by Drug Class (Benzodiazepines, Cannabinoids, Corticosteroids), Route of Administration (Injectable, Oral, Transdermal), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

化療嘔吐治療市場2023年估值為29.4億美元，預計2024年將達到31.3億美元，複合年成長率為6.54%，到2030年將達到45億美元，預計將達到8000萬美元。

化療引起的噁心和嘔吐（CINV）治療市場範圍包括旨在減輕接受化療的癌症患者噁心和嘔吐的治療性介入的開發和分銷。這一點至關重要，因為 CINV 可能對患者的生活品質產生重大影響，並且可能因違規阻礙癌症治療的有效性。這些治療主要應用於臨床環境、醫院和家庭護理環境。主要最終使用者包括醫療保健提供者、癌症治療中心和家庭護理患者。全球癌症發病率不斷上升、治療方法的進步以及對癌症患者支持性護理選擇的認知不斷提高，推動了市場成長。新興機會包括開發新型療法、擴大聯合治療以提高療效，以及使用數位健康平台來改善患者管理和依從性。該研究對市場相關人員的建議包括投資研發以創造新藥，並支持遠端醫療舉措以增強治療和病患監測的機會。然而，市場面臨挑戰，包括對新療法的嚴格監管要求、不同的地區報銷政策以及可能限制市場滲透的高昂藥物開發成本。此外，患者之間治療反應的差異需要個別化的方法，這增加了藥物開發和應用的複雜性。個人化醫療策略的發展、使用人工智慧的治療副作用預測模型以及護理管理平台的整合可能會蓬勃發展。 CINV 治療市場的本質是競爭性和動態性的，需要不斷適應技術進步和監管變化。與生物技術公司和研究機構的策略聯盟和研究合作可以為克服現有限制並透過增強獨特的治療方法和以患者為中心的護理解決方案確保競爭優勢鋪平道路。

主要市場統計
基準年[2023] 29.4億美元
預測年份 [2024] 31.3億美元
預測年份 [2030] 45.8億美元
複合年成長率（%） 6.54%

市場動態：快速發展的化療噁心和嘔吐治療市場的關鍵市場洞察

供需的動態交互作用正在改變化療嘔吐治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於全球癌症發生率上升以及人口老化帶來的醫療支出增加，對 CINV 治療的需求正在增加。
    • 製藥公司、研究機構和醫療保健提供者之間的合作將加速先進 CINV 治療的開發和推廣。
    • 緩釋性和經皮吸收貼片藥物傳遞技術的創新提高了患者對 CINV 治療的依從性和療效。
  • 市場限制因素
    • 醫療保健提供者缺乏關於最新、最有效的 CINV治療方法的足夠培訓和認知。
  • 市場機會
    • 透過與學術機構、生技公司和癌症研究機構的合作，加速新治療方法的開發。
    • 將臨床試驗和治療策略擴展到不同的患者群體，以確保廣泛的適用性和有效性。
  • 市場挑戰
    • 與推出新藥、定價和報銷問題相關的高研發成本和財務風險

波特的五力：導航化療噁心和嘔吐治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解化療噁心和嘔吐治療市場的外部影響

外部宏觀環境因素在塑造化療噁心嘔吐治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解化療噁心嘔吐治療市場的競爭狀況

對化療噁心和嘔吐治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣化療噁心嘔吐治療市場廠商績效評估

FPNV定位矩陣是評估化療引起的噁心嘔吐治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

透過策略分析和建議的化療，繪製噁心嘔吐治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對化療噁心和嘔吐治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率上升以及人口老化帶來的醫療費用上升增加了對 CINV 治療的需求。
      • 製藥公司、研究機構和醫療保健提供者之間的合作將促進先進 CINV 治療方法的開發和推廣。
      • 緩釋性和經皮吸收貼片藥物傳遞技術的創新提高了患者對 CINV 治療的依從性和療效。
    • 抑制因素
      • 醫護人員對最新、最有效的 CINV 治療缺乏足夠的訓練和認知
    • 機會
      • 我們與學術機構、生技公司和癌症研究組織合作，加速新治療方法的開發。
      • 在不同的患者群體中擴大臨床試驗和治療策略，以確保廣泛的適用性和有效性。
    • 任務
      • 將新藥推向市場涉及高昂的研發成本和財務風險，以及定價和報銷問題。
  • 市場區隔分析
    • 藥物類別：苯二氮平類藥物的重要作用，重點在於不同藥物類別的機制和功效
    • 給藥途徑：最佳化 CINV 治療需要評估注射、口服和經皮給藥途徑。
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按藥物類別分類的噁心和嘔吐治療市場（按化療市場分類）

  • 苯二氮平類
  • 大麻素
  • 皮質類固醇
  • 多巴胺拮抗劑
  • NK1受體拮抗劑
  • 血清素受體拮抗劑

第7章化療噁心嘔吐治療市場：依途徑

  • 可注射的
  • 口服
  • 經皮的

第8章化療噁心和嘔吐治療市場：按最終用戶

  • 癌症治療中心
  • 家庭護理設置
  • 醫院

第9章北美及南美化療噁心嘔吐治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區化療噁心嘔吐治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲化療噁心嘔吐治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Astra Zeneca收購 Fusion Pharmaceuticals 以加速放射性結合癌症治療的進展並擴大腫瘤產品線
    • Glenmark 在印度推出注射藥物治療化療引起的噁心和嘔吐
  • 戰略分析和建議
Product Code: MRR-3204321AF679

The Chemotherapy Induced Nausea & Vomiting Treatment Market was valued at USD 2.94 billion in 2023, expected to reach USD 3.13 billion in 2024, and is projected to grow at a CAGR of 6.54%, to USD 4.58 billion by 2030.

The scope of the chemotherapy-induced nausea and vomiting (CINV) treatment market involves developing and distributing therapeutic interventions aimed at alleviating nausea and vomiting in cancer patients undergoing chemotherapy. This is crucial as CINV significantly impacts patients' quality of life and can hinder the effectiveness of cancer treatment due to non-compliance. These treatments are primarily applied in clinical settings, hospitals, and home care environments. Predominant end-users include healthcare providers, cancer treatment centers, and home care patients. Market growth is driven by increasing global cancer prevalence, advancements in treatment modalities, and heightened awareness about supportive care options for cancer patients. Latest opportunities include the development of novel therapeutic agents, expanding the use of combination therapies for enhanced efficacy, and leveraging digital health platforms for patient management and adherence improvement. Recommendations for market players include investing in research and development to create new pharmaceutical agents and supporting telemedicine initiatives to augment treatment accessibility and patient monitoring. However, the market faces challenges such as stringent regulatory requirements for new treatments, varying reimbursement policies across regions, and the high cost of medication development which can limit market penetration. Furthermore, patient-specific variability in treatment response necessitates personalized approaches, adding complexity to drug development and application. Innovation is likely to thrive in the formulation of personalized medicine strategies, artificial intelligence-driven predictive models for treatment side effects, and the integration of care management platforms. The nature of the CINV treatment market is competitive and dynamic, necessitating continuous adaptation to technology advancements and regulatory changes. Engaging in strategic partnerships and collaborations with biotech firms and research institutions may offer pathways to overcome existing limitations and secure a competitive edge through unique therapeutic offerings and enhanced patient-centric care solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 2.94 billion
Estimated Year [2024] USD 3.13 billion
Forecast Year [2030] USD 4.58 billion
CAGR (%) 6.54%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Nausea & Vomiting Treatment Market

The Chemotherapy Induced Nausea & Vomiting Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising global cancer incidence among the aging population and Increasing healthcare expenditures, amplify the need for CINV treatments.
    • Collaborations between pharmaceutical companies, research organizations, and healthcare providers facilitate the development and distribution of advanced CINV treatments.
    • Innovations in drug delivery technologies such as sustained-release formulations and transdermal patches, improve patient compliance and effectiveness of CINV treatments.
  • Market Restraints
    • Lack of adequate training or awareness among healthcare providers regarding the latest and most effective CINV treatments
  • Market Opportunities
    • Partnering with academic institutions, biotech companies, and cancer research organizations to accelerate the development of new treatments.
    • Expanding clinical trials and treatment strategies to include diverse patient populations to ensure broad applicability and effectiveness.
  • Market Challenges
    • High R&D costs and financial risks involved in bringing new drugs to market, coupled with pricing and reimbursement issues

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Nausea & Vomiting Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Nausea & Vomiting Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Nausea & Vomiting Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Nausea & Vomiting Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Nausea & Vomiting Treatment Market

A detailed market share analysis in the Chemotherapy Induced Nausea & Vomiting Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Nausea & Vomiting Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Nausea & Vomiting Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Nausea & Vomiting Treatment Market

A strategic analysis of the Chemotherapy Induced Nausea & Vomiting Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Nausea & Vomiting Treatment Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group plc, Apotex Inc., Astellas Pharma Inc., Baxter International Inc., Dr. Reddy's Laboratories Ltd., Eisai Co., Ltd., Fresenius Kabi AG, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Helsinn Healthcare SA, Lupin Limited, Merck & Co., Inc., Pfizer Inc, Practo Technologies Private Limited, TAIHO PHARMACEUTICAL CO., LTD., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Nausea & Vomiting Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Benzodiazepines, Cannabinoids, Corticosteroids, Dopamine Antagonists, NK1 Receptor Antagonists, and Serotonin Receptor Antagonists.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Transdermal.
  • Based on End User, market is studied across Cancer Treatment Centers, Home Care Settings, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global cancer incidence among the aging population and Increasing healthcare expenditures, amplify the need for CINV treatments.
      • 5.1.1.2. Collaborations between pharmaceutical companies, research organizations, and healthcare providers facilitate the development and distribution of advanced CINV treatments.
      • 5.1.1.3. Innovations in drug delivery technologies such as sustained-release formulations and transdermal patches, improve patient compliance and effectiveness of CINV treatments.
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of adequate training or awareness among healthcare providers regarding the latest and most effective CINV treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Partnering with academic institutions, biotech companies, and cancer research organizations to accelerate the development of new treatments.
      • 5.1.3.2. Expanding clinical trials and treatment strategies to include diverse patient populations to ensure broad applicability and effectiveness.
    • 5.1.4. Challenges
      • 5.1.4.1. High R&D costs and financial risks involved in bringing new drugs to market, coupled with pricing and reimbursement issues
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Significant role of Benzodiazepines focusing on the mechanisms and effectiveness of different drug classes
    • 5.2.2. Route of Administration: Optimizing CINV treatment necessitates evaluation of injectable, oral, and transdermal routes
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Benzodiazepines
  • 6.3. Cannabinoids
  • 6.4. Corticosteroids
  • 6.5. Dopamine Antagonists
  • 6.6. NK1 Receptor Antagonists
  • 6.7. Serotonin Receptor Antagonists

7. Chemotherapy Induced Nausea & Vomiting Treatment Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral
  • 7.4. Transdermal

8. Chemotherapy Induced Nausea & Vomiting Treatment Market, by End User

  • 8.1. Introduction
  • 8.2. Cancer Treatment Centers
  • 8.3. Home Care Settings
  • 8.4. Hospitals

9. Americas Chemotherapy Induced Nausea & Vomiting Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chemotherapy Induced Nausea & Vomiting Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chemotherapy Induced Nausea & Vomiting Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. AstraZeneca acquires Fusion Pharmaceuticals to accelerate radio conjugate cancer treatment advancements and expand oncology pipeline
    • 12.3.2. Glenmark Launches Injection to Combat Chemotherapy-Induced Nausea and Vomiting in India
  • 12.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CANNABINOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY NK1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY SEROTONIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. CHEMOTHERAPY INDUCED NAUSEA & VOMITING TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023